Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Study acronym: ICT-HCC
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Mar 15, 2027 → Dec 15, 2027
Enrollment reduced 10% 300 → 270 participants
See other at-risk trials from Nanjing Tianyinshan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 15, 2027 to Dec 15, 2027 Show 6 more changesShow less
    • Enrollment reduced: 300 → 270 participants
    • Study completion pushed from Mar 15, 2028 to Dec 15, 2028
    • Interventions modified
    • Trial arms changed: 10 → 9
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 15, 2025 to May 22, 2025
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.
Trial Details
NCT Number NCT06893887
Lead Sponsor Nanjing Tianyinshan Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma(HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov